Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14636020 | 0.95 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL14636952 | 0.87 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL14636039 | 0.86 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL1394155 | 0.86 | MCHR1 (0.75) | MCHR1KCNH2HRH3 | |
| SCHEMBL113372 | 0.84 | MCHR1 (0.79) | MCHR1KCNH2HRH3 | |
| SCHEMBL326652 | 0.83 | MCHR1 (0.73) | MCHR1KCNH2 | |
| SCHEMBL322358 | 0.83 | MCHR1 (0.70) | MCHR1KCNH2 | |
| SCHEMBL14636021 | 0.82 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL14636756 | 0.82 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL322758 | 0.81 | MCHR1 (0.72) | MCHR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2731950-A1 | AZETIDINE DERIVATIVES FOR TREATMENT OF MELANIN RELATED DISORDERS | AstraZeneca AB (SE) | 2014-05-21 | — | — | EP | claimed |
| US-20130184250-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2013-07-18 | — | — | US | claimed |
| WO-2013011285-A1 | AZETIDINE DERIVATIVES FOR TREATMENT OF MELANIN RELATED DISORDERS | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-2731950-A1 | AZETIDINE DERIVATIVES FOR TREATMENT OF MELANIN RELATED DISORDERS | AstraZeneca AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130184250-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184250-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184250-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2013-07-18 | — | — | US | disclosed |
| WO-2013011285-A1 | AZETIDINE DERIVATIVES FOR TREATMENT OF MELANIN RELATED DISORDERS | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013011285-A1 | AZETIDINE DERIVATIVES FOR TREATMENT OF MELANIN RELATED DISORDERS | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184250-A1 | Therapeutic Agents | TYR, MC1R, MCHR1 | MCHR1 3/4885KCNH2 4206/4885HRH3 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.